Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .
Microvascular endothelial function in subjects with Type 2 diabetes and the effect of lipid-lowering therapy.
AIMS Abnormalities of microvascular and endothelial function are present in subjects with Type 2 diabetes . Although statin therapy improves cardiovascular risk in diabetes , dyslipidaemia in diabetes may be more responsive to combined statin and fibrate therapy . We examined the effect of cerivastatin and fenofibrate on microvascular function in subjects with Type 2 diabetes with no clinical evidence of cardiovascular disease and near normal lipid levels . METHODS Age- , sex- , lipid- and blood pressure-matched subjects with Type 2 diabetes were r and omized in double-blind fashion to one of four treatment groups : group 1 placebo/placebo ( n=12 ) , group 2 fenofibrate/placebo ( n=10 ) , group 3 cerivastatin/placebo ( n=20 ) and group 4 cerivastatin/fenofibrate ( n=11 ) . The subjects were recruited from the Lipid in Diabetes Study .  Microvascular function was assessed by skin blood flow response to iontophoresis of acetylcholine and sodium nitroprusside and by skin maximum hyperaemia to local heating . Measurements were carried out at baseline and 3 months later . RESULTS Although all lipid parameters improved in groups 2 - 4 after 3 months ' therapy , no difference was detected in skin blood flow to iontophoresis or maximum hyperaemia in any of the groups . Highly sensitive c-reactive protein ( Hs-CRP ) did not change with therapy . CONCLUSIONS In conclusion , we were unable to demonstrate any improvement in microvascular endothelial function in non-hyperlipidaemic Type 2 diabetic subjects treated with single or combination lipid-lowering therapy
Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .